Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64179375 versus apixaban after elective total knee replacement
2016-004550-15Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in venous thromboembolism (VTE) comparing JNJ-64179375 arm with Apixaban arm (2 arms). Primary endpoints: Safety and tolerability for dose escalation in Part 1, Bleeding events for dose selection and 1 more. Started Jul 2017; status: completed.
02
Drugs
ichorcumabapixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2016-004550-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004550-15.